Compare Gitlab Inc (GTLB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Inovio Pharmaceuticals Inc — how do they compare? Gitlab Inc trades at $55.07 (market cap $8.92B), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $112.19M). The key difference: Gitlab Inc is far larger — about 79.5× Inovio Pharmaceuticals Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| GTLB | INO | |
|---|---|---|
Market Cap | $8.92B | $112.19M |
Volume | 4,716,893 | 3,201,278 |
Sector | Technology | Health |
52-Week High | $53.56 | $2.65 |
52-Week Low | $19.42 | $0.66 |
Typical Hold Time | 62 Days | 43 Days |
Enterprise Value | $7.66B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) is trading at $54.74, up 5.29% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust at 21.3% year-over-year in Q2 2026, though the company continues to operate at a net loss. Recent news highlights strong AI-driven demand and improved sales momentum, with the company raising its full-year guidance.
The outlook is cautiously optimistic with significant revenue growth potential from AI integration, but high valuation multiples and persistent profitability challenges present risks. Analyst consensus leans neutral with a $49.71 price target below current levels, suggesting limited near-term upside despite positive business developments.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
